News Releases

NEW ORLEANS, Oct. 27, 2016 /PRNewswire/ -- Novo Nordisk, a global leader in obesity care, today announced that data from eight abstracts, including six posters and two oral presentations, will be shared at ObesityWeek 2016, the 4^th annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in New Orleans, LA, from October 31 to November 5. Of note, early responder data from the SCALE^™ clinical trial program was selected as one of five manuscripts to be presented at the congress's Obesity Journal Symposium, comprised of selected papers providing the latest insights into preventing and treating obesity.

In addition to new results from the SCALE^™ clinical trial program, this year at ObesityWeek, Novo Nordisk will release quantitative data for the first time from the Awareness, Care & Treatment In Obesity Management (ACTION) study, the first U.S. nationwide study to investigate barriers to obesity management from the perspective of people with obesity, health care professionals and employers.

The following are key highlights that will be presented at the meeting:

Wednesday, November 2, 3:30 PM CDT/4:30 PM EDT, journal symposium oral presentation

• Results from pooled Phase 3a SCALE™ clinical trial data – Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in cardiometabolic risk factors.

Wednesday, November 2, 12:00 PM CDT/1:00 PM EDT, poster presentation

• Data from the national ACTION study relating to insights and perceptions of obesity management in people with obesity (#T-P-3178)

Thursday, November 3, 3:45 PM CDT/4:45 PM EDT, oral presentation

• Data from the ACTION study relating to divergences in perceptions and attitudes among people with obesity, healthcare professionals and employers, resulting in barriers to effective obesity management (T-OR-2088)

Friday, November 4, 12:00 PM CDT/1:00 PM EDT, poster presentation

• Phase 3a post-hoc analysis from the 3-year part of the SCALE™ obesity and pre-diabetes trial comparing efficacy and safety of liraglutide for adults with pre-diabetes and BMI <35 vs ≥35 kg/m² at baseline (T-P-3474)

Friday, November 4, 12:00 PM CDT/1:00 PM EDT, poster presentation

• Phase 3a post-hoc analysis from the 3-year part of the SCALE™ obesity and pre-diabetes trial exploring the impact of weight loss on health-related quality of life (HRQoL) in people with pre-diabetes and obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with hypertension and/or dyslipidemia as measured by IWQOL-Lite (T-P-3477)

Friday, November 4, 12:00 PM EDT/1:00 PM CST, poster presentation

• Phase 3a post-hoc analysis from the 3-year part of the SCALE™ obesity and pre-diabetes trial exploring the impact of weight loss on health-related quality of life (HRQoL) in people with pre-diabetes and obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m2) with hypertension and/or dyslipidemia as measured by SF-36 (T-P-3469)

"Novo Nordisk is proud to have a strong presence at ObesityWeek 2016, where we will share new research related to obesity management attitudes and behaviors along with insightful clinical data," said Dr. Todd Hobbs, Chief Medical Officer, Novo Nordisk US. "The research being presented demonstrates our continued commitment to improving care and treatment options for people living with this complex disease by driving scientific progress and understanding in the obesity area."

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people with other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has more than 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.

SCALE™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2016 Novo Nordisk   All rights reserved.   USA16SAM04080   October 2016

SOURCE Novo Nordisk Inc.